RESUMO
PURPOSE: Overweight and obesity are major public health concerns worldwide which are associated with a low-grade chronic inflammation. Dietary fiber as an important component of diet could be effective in controlling weight and inflammatory factors. The present study aimed to compare the effects of rice husk powder and rice bran on inflammatory factors along with an energy-restricted diet in overweight and obese adults. METHODS: In this randomized trial, 105 eligible individuals were assigned to one of the three energy-restricted diet groups receiving; rice bran (n = 35), rice husk powder (n = 35), and control group (n = 35) for 12 weeks. Demographic data, dietary intake, anthropometric indices and inflammatory factors (serum levels of IL-6 and hs-CRP) were measured at baseline and at the end of the study. RESULTS: Weight, BMI and waist circumference reduced significantly in all groups after 12 weeks of study (P < 0.01 for all). However, pre- and post-measure differences between groups were not significant. Moreover, serum levels of hs-CRP and IL-6 were not significantly different between participants in the rice bran or rice husk groups. However, the reduction in serum levels of hs-CRP in rice husk (mean change = - 0.14 ± 0.05 µg/ml) and rice bran (mean change = - 0.13 ± 0.03 µg/ml) was significantly higher when compared to the control group (mean change = - 0.03 ± 0.02 µg/ml) (P < 0.05 for both groups). The same pattern was found when changes in IL-6 serum levels of participants in rice husk (mean change = - 0.48 ± 0.11 pg/ml) and rice bran (mean change = - 0.57 ± 0.13 pg/ml) groups were compared to the control group (mean change= - 0.19 ± 0.07 pg/ml) (P < 0.05 for both groups). CONCLUSION: The results of this study showed positive effects of rice bran and rice husk powder supplementation, combined with an energy-restricted diet, on inflammatory markers among overweight and obese adults.
Assuntos
Anti-Inflamatórios/uso terapêutico , Dieta Redutora , Fibras na Dieta/uso terapêutico , Obesidade/dietoterapia , Oryza/química , Sobrepeso/dietoterapia , Prebióticos , Adulto , Anti-Inflamatórios/efeitos adversos , Anti-Inflamatórios/economia , Índice de Massa Corporal , Registros de Dieta , Dieta Redutora/efeitos adversos , Fibras na Dieta/efeitos adversos , Fibras na Dieta/economia , Ingestão de Energia , Feminino , Indústria de Processamento de Alimentos/economia , Humanos , Resíduos Industriais/análise , Resíduos Industriais/economia , Mediadores da Inflamação/sangue , Irã (Geográfico) , Masculino , Pessoa de Meia-Idade , Obesidade/sangue , Obesidade/economia , Obesidade/imunologia , Sobrepeso/sangue , Sobrepeso/economia , Sobrepeso/imunologia , Cooperação do Paciente , Prebióticos/efeitos adversos , Prebióticos/economia , Resposta de Saciedade , Redução de PesoRESUMO
Oligosaccharides and dietary fibres are non-digestible food ingredients that preferentially stimulate the growth of prebiotic Bifidobacterium and other lactic acid bacteria in the gastro-intestinal tract. Xylooligosaccharides (XOS) provide a plethora of health benefits and can be incorporated into several functional foods. In the recent times, there has been an over emphasis on the microbial conversion of agroresidues into various value added products. Xylan, the major hemicellulosic component of lignocellulosic materials (LCMs), represents an important structural component of plant biomass in agricultural residues and could be a potent bioresource for XOS. On an industrial scale, XOS can be produced by chemical, enzymatic or chemo-enzymatic hydrolysis of LCMs. Chemical methods generate XOS with a broad degree of polymerization (DP), while enzymatic processes will be beneficial for the manufacture of food grade and pharmaceutically important XOS. Xylooligomers exert several health benefits, and therefore, have been considered to provide relief from several ailments. This review provides a brief on production, purification and structural characterization of XOS and their health benefits.
Assuntos
Produtos Agrícolas/química , Glucuronatos , Oligossacarídeos , Prebióticos , Resíduos/análise , Adjuvantes Imunológicos/economia , Adjuvantes Imunológicos/isolamento & purificação , Adjuvantes Imunológicos/farmacologia , Adjuvantes Imunológicos/uso terapêutico , Animais , Anticarcinógenos/economia , Anticarcinógenos/isolamento & purificação , Anticarcinógenos/farmacologia , Anticarcinógenos/uso terapêutico , Antioxidantes/economia , Antioxidantes/isolamento & purificação , Antioxidantes/farmacologia , Antioxidantes/uso terapêutico , Biomassa , Configuração de Carboidratos , Sequência de Carboidratos , Cromatografia/métodos , Produtos Agrícolas/economia , Fibras na Dieta/análise , Proteínas Fúngicas/metabolismo , Trato Gastrointestinal/microbiologia , Glucuronatos/economia , Glucuronatos/isolamento & purificação , Glucuronatos/farmacologia , Glucuronatos/uso terapêutico , Glicosídeo Hidrolases , Humanos , Hidrólise , Lignina/análise , Microbiota/efeitos dos fármacos , Dados de Sequência Molecular , Estrutura Molecular , Oligossacarídeos/economia , Oligossacarídeos/isolamento & purificação , Oligossacarídeos/farmacologia , Oligossacarídeos/uso terapêutico , Prebióticos/economia , Ultrafiltração , Resíduos/economia , Xilanos/químicaRESUMO
There is limited evidence on the effects of prebiotics on inflammation. Therefore, the aim of this study was to evaluate the effects of inulin supplementation on inflammatory indices and metabolic endotoxemia in patients with type 2 diabetes mellitus. The participants included diabetic females (n = 49). They were divided into an intervention group (n = 24) as well as a control group (n = 25) and received 10 g/d inulin or maltodextrin for 8 weeks, respectively. Fasting blood sugar (FBS), HbA1c, insulin, high-sensitive C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-α), interleukin-10 (IL-10), and plasma lipopolysaccharide (LPS) were measured pre and post intervention. Inulin-supplemented patients exhibited a significant decrease in FBS (8.5%), HbA1c (10.4%), fasting insulin (34.3%), homeostasis model assessment of insulin resistance (HOMA-IR) (39.5%), hs-CRP (35.6%), TNF-α (23.1%), and LPS (27.9%) compared with the maltodextrin group (p < 0.05). Increase in IL-10 was not significant in inulin compared with the maltodextrin group. It can be concluded that inulin supplementation seems to be able to modulate inflammation and metabolic endotoxemia in women with type 2 diabetes.
Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Diabetes Mellitus Tipo 2/dietoterapia , Endotoxemia/complicações , Inulina/uso terapêutico , Obesidade/complicações , Sobrepeso/complicações , Prebióticos , Adulto , Idoso , Anti-Inflamatórios não Esteroides/economia , Índice de Massa Corporal , Terapia Combinada , Diabetes Mellitus Tipo 2/complicações , Diabetes Mellitus Tipo 2/tratamento farmacológico , Diabetes Mellitus Tipo 2/imunologia , Método Duplo-Cego , Endotoxemia/sangue , Endotoxemia/imunologia , Feminino , Seguimentos , Humanos , Hipoglicemiantes/uso terapêutico , Imunomodulação , Resistência à Insulina , Inulina/economia , Irã (Geográfico) , Lipopolissacarídeos/antagonistas & inibidores , Lipopolissacarídeos/sangue , Pessoa de Meia-Idade , Obesidade/imunologia , Sobrepeso/imunologia , Prebióticos/economia , Adulto JovemRESUMO
Campylobacter is a food safety hazard, which causes a substantial human disease burden. Infected broiler meat is a common source of campylobacteriosis. The use of probiotics, prebiotics, or synbiotics has been associated with controlling Campylobacter infections in broilers, although efficacy remains a contentiously debated issue. On-farm use of probiotics, prebiotics, or synbiotics is gaining momentum. Therefore, it is interesting to analyze the economic viability of this potential intervention to reduce Campylobacter prevalence in broilers. A normative cost-effectiveness analysis was conducted to estimate the cost-effectiveness ratio of using probiotics, prebiotics, or synbiotics in broiler production in Denmark, the Netherlands, Poland, and Spain. The cost-effectiveness ratio was defined as the estimated costs of probiotics, prebiotics, or synbiotics use divided by the estimated public health benefits expressed in euro () per avoided disability-adjusted life year (DALY). The model considered differences between the countries in zootechnical and economic farm performance, in import, export, and transit of live broilers, broiler meat and meat products, and in disease burden of Campylobacter-related human illness. Simulation results revealed that the costs per avoided DALY were lowest in Poland and Spain (4,000-30,000 per avoided DALY) and highest in the Netherlands and Denmark (70,000-340,000 per avoided DALY) at an efficacy ranging from 10 to 20%. In Poland and Spain, using probiotics can be classified as a moderately expensive intervention if efficacy is more than 10%, otherwise it is relatively expensive. In the Netherlands and Denmark, using probiotics is a relatively expensive intervention irrespective of efficacy. However, if probiotics, prebiotics, or synbiotics were assumed to enhance broiler performance, it would become a relatively cost-effective intervention for Campylobacter even at low efficacy levels of 1 to 10%.
Assuntos
Infecções por Campylobacter , Galinhas , Análise Custo-Benefício , Prebióticos , Probióticos , Simbióticos , Animais , Campylobacter , Infecções por Campylobacter/economia , Infecções por Campylobacter/prevenção & controle , Infecções por Campylobacter/veterinária , Galinhas/microbiologia , Países Baixos , Polônia , Prebióticos/economia , Probióticos/economia , Espanha , Simbióticos/economiaRESUMO
BACKGROUND: The rates of pre-diabetes and type 2 diabetes mellitus are increasing worldwide, producing significant burdens for individuals, families, and healthcare systems. In New Zealand, type 2 diabetes mellitus and pre-diabetes disproportionally affect Maori, Pacific, and South Asian peoples. This research evaluates the efficacy, acceptability, and economic impact of a probiotic capsule and a prebiotic cereal intervention in adults with pre-diabetes on metabolic and mental health and well-being outcomes. METHODS: Eligible adults (n = 152) aged 18-80 years with pre-diabetes (glycated haemoglobin 41-49 mmol/mol) will be enrolled in a 2 × 2 factorial design, randomised, parallel-group, placebo-controlled trial. Computer-generated block randomization will be performed independently. Interventions are capsulated Lactobacillus rhamnosus HN001 (6 × 109 colony-forming units/day) (A) and cereal containing 4 g ß-glucan (B), placebo capsules (O1), and calorie-matched control cereal (O2). Eligible participants will receive 6 months intervention in the following groups: AB, AO1, BO2, and O1O2. The primary outcome is glycated haemoglobin after 6 months. Follow-up at 9 months will assess the durability of response. Secondary outcomes are glycated haemoglobin after 3 and 9 months, fasting glucose, insulin resistance, blood pressure, body weight, body mass index, and blood lipid levels. General well-being and quality of life will be measured by the Short-Form Health Survey 36 and Depression Anxiety Stress Scale 21 at 6 and 9 months. Outcome assessors will be blind to capsule allocation. An accompanying qualitative study will include 24 face-to-face semistructured interviews with an ethnically balanced sample from the ß-glucan arms at 2 months, participant focus groups at 6 months, and three health professional focus groups. These will explore how interventions are adopted, their acceptability, and elicit factors that may support the uptake of interventions. A simulation model of the pre-diabetic New Zealand population will be used to estimate the likely impact in quality-adjusted life years and health system costs of the interventions if rolled out in New Zealand. DISCUSSION: This study will examine the efficacy of interventions in a population with pre-diabetes. Qualitative components provide rich description of views on the interventions. When combined with the economic analysis, the study will provide insights into how to translate the interventions into practice. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry, ACTRN12617000990325. Prospectively registered on 10 July 2017.
Assuntos
Hemoglobinas Glicadas/metabolismo , Lacticaseibacillus rhamnosus/fisiologia , Estado Pré-Diabético/dietoterapia , Probióticos/administração & dosagem , beta-Glucanas/administração & dosagem , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/sangue , Cápsulas , Análise Custo-Benefício , Feminino , Custos de Cuidados de Saúde , Nível de Saúde , Humanos , Masculino , Pessoa de Meia-Idade , Nova Zelândia , Prebióticos/administração & dosagem , Prebióticos/efeitos adversos , Prebióticos/economia , Estado Pré-Diabético/sangue , Estado Pré-Diabético/economia , Estado Pré-Diabético/microbiologia , Probióticos/efeitos adversos , Probióticos/economia , Pesquisa Qualitativa , Ensaios Clínicos Controlados Aleatórios como Assunto , Fatores de Tempo , Resultado do Tratamento , Adulto Jovem , beta-Glucanas/efeitos adversos , beta-Glucanas/economiaRESUMO
Antibiotics have been used for many years as growth promoters. They contribute to build the immunocompetence (i.e. ability of the body to produce a normal immune response following exposure to an antigen) of birds against infectious diseases and as growth promoters. Antibiotics have been widely used as growth promoters in the field of animal production since 1940s. There is a hypothesis that is effect is brought about by dynamic biological interaction with the micro-flora in the intestine. In 1951, the United States Food and Drug Administration approved the use of antibiotics as animal additives to prevent disease in general and, in some cases, to improve efficiency without veterinary prescription. In the 1950s and 1960s, each European state approved its own national regulations about the use of antibiotics in animal feeds. However, using antibiotics may develop bacteria resistant to these drugs. Accordingly, the use of antibiotics has been minimized and replaced by effective dietary supplements such as probiotics and/or prebiotics that are claimed to enhance growth and positively modulate the immune response. The current review paper sheds light on the benefits of using probiotics and/or prebiotics in poultry feed versus the risk of using antibiotics and the mechanisms by which they exert their effects, as well as the economic analysis of using these beneficial additives in poultry feed.
Assuntos
Ração Animal/análise , Criação de Animais Domésticos/métodos , Prebióticos/administração & dosagem , Probióticos/administração & dosagem , Ração Animal/economia , Animais , Galinhas , Prebióticos/economia , Probióticos/economia , PerusRESUMO
Nowadays, the strong relationship between diet and health is well known. Although the primary role of diet is to provide nutrients to fulfill metabolic requirements, the use of foods to improve health and the state of well-being is an idea increasingly accepted by society in the last three decades. During the last years, an important number of scientific advances have been achieved in this field and, although in some situations, it is difficult to establish a distinction between "harmful" and "good" bacteria, experts agree in classifying the genera Bifidobacterium and Lactobacillus as beneficial bacteria. Thus, several strategies can be used to stimulate the proliferation of these beneficial intestinal bacteria, being one of them the consumption of prebiotics. The development of new prebiotics, with added functionality, is one of the most serious challenges shared not only by the scientific community but also by the food industry. The objective of this work was to evaluate the potential prebiotic effect of red and white grape residues, both obtained during the winemaking process. For such purpose, an in vitro study with pure cultures of Lactobacillus and Bifidobacterium was first conducted. Secondly, a study with mixed cultures using human fecal inocula was carried out in a simulator of the distal part of the colon. The obtained results showed an increase in the Lactobacillus and Bifidobacterium population, indicating that these ingredients are serious candidates to be considered as prebiotics.
Assuntos
Microbioma Gastrointestinal , Modelos Biológicos , Pigmentos Biológicos/metabolismo , Componentes Aéreos da Planta/química , Extratos Vegetais/metabolismo , Prebióticos , Vitis/química , Adulto , Animais , Bifidobacterium/classificação , Bifidobacterium/crescimento & desenvolvimento , Bifidobacterium/isolamento & purificação , Bifidobacterium/metabolismo , Digestão , Fezes/microbiologia , Feminino , Fermentação , Indústria de Processamento de Alimentos/economia , Humanos , Resíduos Industriais/análise , Resíduos Industriais/economia , Lactobacillus/classificação , Lactobacillus/crescimento & desenvolvimento , Lactobacillus/isolamento & purificação , Lactobacillus/metabolismo , Masculino , Viabilidade Microbiana , Tipagem Molecular , Componentes Aéreos da Planta/metabolismo , Extratos Vegetais/economia , Prebióticos/economia , Espanha , Vitis/metabolismoRESUMO
Carrot pomace is an abundant, but underutilized, byproduct from the juice industry. In this study, the insoluble dietary fiber from carrot pomace was treated using an ultra-microgrinding process, and the resulting changes in its physicochemical properties and intestinal protective effect against heavy metal damage were examined. The SEM and fluorescence microscopy results showed that the grinding process could significantly decrease the particle size of carrot insoluble dietary fibre and increase its Brunauer-Emmett-Teller surface area from 0.374 to 1.835 m(2) g(-1). Correspondingly, the water-holding capacity, swelling capacity, and oil-holding capacity increased by 62.09%, 49.25% and 45.45%, respectively. The glucose-, nitrite-, and lead ion-adsorbing abilities also improved significantly compared with the raw samples. In addition, apoptosis assessment by AO/EB revealed that the ground fibre could effectively protect Caco-2 cells from lead ion damage. The MTT assay showed that carrot insoluble dietary fibre has no toxicity for Caco-2 cells at a concentration of 10.0 mg L(-1). The findings of this study highlighted the potential of the ultra-microgrinding process to produce a high added-value fibre ingredient from carrot residues.
Assuntos
Daucus carota/química , Enterócitos/metabolismo , Raízes de Plantas/química , Prebióticos , Substâncias Protetoras/metabolismo , Apoptose/efeitos dos fármacos , Células CACO-2 , Quelantes/efeitos adversos , Quelantes/química , Quelantes/metabolismo , Fenômenos Químicos , China , Daucus carota/economia , Enterócitos/citologia , Enterócitos/efeitos dos fármacos , Manipulação de Alimentos , Indústria de Processamento de Alimentos/economia , Humanos , Resíduos Industriais/análise , Resíduos Industriais/economia , Chumbo/química , Chumbo/metabolismo , Chumbo/toxicidade , Intoxicação por Chumbo/prevenção & controle , Microscopia Eletrônica de Varredura , Tamanho da Partícula , Prebióticos/efeitos adversos , Prebióticos/análise , Prebióticos/economia , Substâncias Protetoras/efeitos adversos , Substâncias Protetoras/química , Substâncias Protetoras/economia , Solubilidade , Propriedades de SuperfícieRESUMO
Barley husks, rye bran, and a fiber residue from oat milk production were processed by heat pretreatment, various separation steps, and treatment with an endoxylanase in order to improve the prebiotic potential of these cereal byproducts. Metabolic functions were intended to improve along with improved microbial activity. The products obtained were included in a high-fat mouse diet so that all diets contained 5% dietary fiber. In addition, high-fat and low-fat controls as well as partially hydrolyzed guar gum were included in the study. The soluble fiber product obtained from rye bran caused a significant increase in the bifidobacteria (log copies of 16S rRNA genes; median (25-75 percentile): 6.38 (6.04-6.66) and 7.47 (7.30-7.74), respectively; p < 0.001) in parallel with a tendency of increased production of propionic acid and indications of improved metabolic function compared with high-fat fed control mice. The oat-derived product caused an increase in the pool of cecal propionic (from 0.62 ± 0.12 to 0.94 ± 0.08) and butyric acid (from 0.38 ± 0.04 to 0.60 ± 0.04) compared with the high-fat control, and it caused a significant increase in lactobacilli (log copies of 16S rRNA genes; median (25-75 percentile): 6.83 (6.65-7.53) and 8.04 (7.86-8.33), respectively; p < 0.01) in the cecal mucosa. However, no changes in measured metabolic parameters were observed by either oat or barley products.
Assuntos
Avena/química , Hordeum/química , Resíduos Industriais/análise , Resistência à Insulina , Obesidade/dietoterapia , Prebióticos , Secale/química , Animais , Bifidobacterium/crescimento & desenvolvimento , Bifidobacterium/isolamento & purificação , Bifidobacterium/metabolismo , Ceco/metabolismo , Ceco/microbiologia , Dieta Hiperlipídica/efeitos adversos , Ácidos Graxos Voláteis/metabolismo , Indústria de Processamento de Alimentos/economia , Temperatura Alta , Hidrólise , Resíduos Industriais/economia , Mucosa Intestinal/metabolismo , Mucosa Intestinal/microbiologia , Lactobacillaceae/crescimento & desenvolvimento , Lactobacillaceae/isolamento & purificação , Lactobacillaceae/metabolismo , Masculino , Camundongos Endogâmicos C57BL , Obesidade/etiologia , Obesidade/metabolismo , Obesidade/microbiologia , Prebióticos/economia , SuéciaRESUMO
Production of prebiotic carbohydrates at competitive prices is a challenge nowadays since the well-established production processes involve many purification steps which are labour intensive and require important amounts of reagents and products thus increasing prebiotic's price. Several processes have been studied in our laboratory involving the use of Supercritical Fluid Technology to fractionate and purify carbohydrate solid mixtures. Research carried out at laboratory scale using theoretical mixtures (lactose/lactulose and galactose/tagatose), commercially available carbohydrate mixtures and carbohydrate mixtures produced by enzymatic transglycosylation and isomerized with complexating reagents demonstrated that purification of prebiotic carbohydrates was technically possible by supercritical fluid extraction. In the present work, the process optimized at laboratory scale to fractionate carbohydrate mixtures produced by enzymatic transglycosylation has been scaled-up to an industrial level and its economic feasibility has been simulated employing AspenONE(®) V7.3 software to obtain consistent data supporting the interest of a potential investment for prebiotics production at large scale using supercritical fluids.
Assuntos
Carboidratos/isolamento & purificação , Cromatografia com Fluido Supercrítico/métodos , Prebióticos/análise , Carboidratos/química , Simulação por Computador , Estudos de Viabilidade , Prebióticos/economiaRESUMO
UNLABELLED: The objective of this study was to assess the cost-effectiveness of the use of prebiotics for the primary prevention of atopic dermatitis in The Netherlands. A model was constructed using decision analytical techniques. The model was developed to estimate the health economic impact of prebiotic preventive disease management of atopic dermatitis. Data sources used include published literature, clinical trials and official price/tariff lists and national population statistics. The comparator was no supplementation with prebiotics. The primary perspective for conducting the economic evaluation was based on the situation in The Netherlands in 2009. The results show that the use of prebiotics infant formula (IMMUNOFORTIS(®)) leads to an additional cost of 51 and an increase in Quality Adjusted Life Years (QALY) of 0.108, when compared with no prebiotics. Consequently, the use of infant formula with a specific mixture of prebiotics results in an incremental cost-effectiveness ratio (ICER) of 472. The sensitivity analyses show that the ICER remains in all analyses far below the threshold of 20,000/QALY. CONCLUSION: This study shows that the favourable health benefit of the use of a specific mixture of prebiotics results in positive short- and long-term health economic benefits. In addition, this study demonstrates that the use of infant formula with a specific mixture of prebiotics is a highly cost-effective way of preventing atopic dermatitis in The Netherlands.
Assuntos
Modelos Econométricos , Prebióticos/economia , Asma/prevenção & controle , Criança , Pré-Escolar , Análise Custo-Benefício , Bases de Dados Factuais , Dermatite Atópica/prevenção & controle , Humanos , Lactente , Fórmulas Infantis , Países Baixos , Prevenção Primária/economiaRESUMO
The production of new bioactive oligosaccharides is currently garnering much attention for their potential use as functional ingredients. This work addresses the enzymatic synthesis and NMR structural characterization of 2-α-D-glucopyranosyl-lactose derived from sucrose:lactose and sucrose:cheese whey permeate mixtures by using a Leuconostoc mesenteroides B-512F dextransucrase. The effect of synthesis conditions, including concentration of substrates, molar ratio of donor/acceptor, enzyme concentration, reaction time, and temperature, on the formation of transfer products is evaluated. Results indicated that cheese whey permeate is a suitable material for the synthesis of 2-α-D-glucopyranosyl-lactose, giving rise to yields around 50% (in weight respect to the initial amount of lactose) under the optimum reaction conditions. According to its structure, this trisaccharide is an excellent candidate for a new prebiotic ingredient, due to the reported high resistance of α-(1â2) linkages to the digestive enzymes in humans and animals, as well as to its potential selective stimulation of beneficial bacteria in the large intestine mainly attributed to the two linked glucose units located at the reducing end that reflects the disaccharide kojibiose (2-α-D-glucopyranosyl-D-glucose). These findings could contribute to broadening the use of important agricultural raw materials, such as sucrose or cheese whey permeates, as renewable substrates for enzymatic synthesis of oligosaccharides of nutritional interest.
Assuntos
Queijo/análise , Queijo/microbiologia , Glucosiltransferases/metabolismo , Leuconostoc/enzimologia , Prebióticos/análise , Sacarose/metabolismo , Trissacarídeos/metabolismo , Proteínas de Bactérias/metabolismo , Indústria de Processamento de Alimentos/economia , Resíduos Industriais/análise , Resíduos Industriais/economia , Prebióticos/economia , Espanha , Trissacarídeos/química , Trissacarídeos/isolamento & purificaçãoRESUMO
The cost/benefit ratio of probiotics in the ambulatory treatment of acute infectious gastro-enteritis with or without a synbiotic food supplement (containing fructo-oligosaccharides and probiotic strains of Streptoccoccus thermophilus, Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium lactis and Bifidobacterium infantis) has been studied. 111 children (median age 37 and 43 months for the synbiotic and placebo group, respectively) with acute infectious gastroenteritis were included in a randomised, prospective placebo-controlled trial performed in primary health care. All children were treated with an oral rehydration solution and with the synbiotic food supplement (n=57) or placebo (n=54). Physicians were allowed to prescribe additional medication according to what they considered as 'necessary'. Cost of add-on medication and total healthcare cost were calculated. Median duration of diarrhoea was 1 day shorter (95% confidence interval -0.6 to -1.9 days) in the symbiotic than in the placebo group (P<0.005). Significantly more concomitant medication (antibiotics, antipyretics, antiemetics) was prescribed in the placebo group (39 prescriptions in 28 patients) compared to the synbiotic group (12 prescriptions in 7 patients) (P<0.001). The difference was most striking for antiemetics: 28 vs. 5 prescriptions. The cost of add-on medication in the placebo group was evaluated at 4.04/patient (median 4.97 (interquartile (IQ) 25-75: 0-4.97)) vs. 1.13 /patient in the synbiotic arm (P<0.001). If the cost of the synbiotic is considered, median cost raised to 7.15/patient (IQ 25-75: 7.15-7.15) (P<0.001). The extra consultations needed to prescribe the concomitant medication resulted in a higher health care cost in the placebo group ( 14.41 vs. 10.74/patient, P<0.001). Synbiotic food supplementation resulted in a 24 h earlier normalisation of stool consistency. Although use of the synbiotic supplementation increased cost, add-on medication and extra consultations were reduced, resulting in a reduction of health care cost of 25%.
Assuntos
Gastroenterite/economia , Gastroenterite/terapia , Simbióticos/economia , Doença Aguda/economia , Doença Aguda/terapia , Adolescente , Criança , Pré-Escolar , Análise Custo-Benefício , Humanos , Lactente , Masculino , Prebióticos/economia , Prebióticos/estatística & dados numéricos , Probióticos/economia , Probióticos/uso terapêutico , Estudos Prospectivos , Simbióticos/estatística & dados numéricosRESUMO
The aim of this study was to evaluate the efficacy of colostrum (ARD Colostrum) in association with the immunomodulator Bifivir in the prevention of flu episodes compared with anti-flu vaccination. The registry groups included no prevention, vaccination, vaccination+immunomodulators, and immunomodulators only. Groups were comparable for age and sex distribution. In the group without prevention there were 8 major episodes and 12 minor episodes out of 34 subjects (8-12/34); in the vaccination group the respective figures were 8-13/38; in the group treated with a combination of vaccination and immunomodulators (ARD Colostrum + Bifivir) the figures were 4-9/33; and in the group treated with immunomodulators only there were 11 viral episodes (3-8) in 36 subjects. The episodes in the vaccination+immunomodulators and immunomodulators only groups were significantly lower compared with the other two groups (P<0.05). The number of episodes registered with the immunnomodulators was significantly lower than those observed in patients using vaccination or no prevention (P<0.05). The number of days of disease was higher in untreated controls compared to the groups treated with immunomodulators (P<0.05) and 2 times higher in the vaccination group compared to the same groups (P<0.05). The average relative costs were significantly lower (2.3 times) in the immunomodulators groups in comparison with the other groups (P<0.05). No problems concerning tolerability or side effects were observed during the study. Compliance was very good. In conclusion, the administration of immunomodulators is very cost effective and appears to be more effective than vaccination to prevent flu.
Assuntos
Colostro/imunologia , Fatores Imunológicos/uso terapêutico , Vacinas contra Influenza , Influenza Humana/prevenção & controle , Prebióticos , Probióticos/uso terapêutico , Idoso , Análise de Variância , Análise Custo-Benefício , Custos de Medicamentos , Feminino , Custos Hospitalares , Humanos , Fatores Imunológicos/efeitos adversos , Fatores Imunológicos/economia , Vacinas contra Influenza/economia , Influenza Humana/economia , Influenza Humana/epidemiologia , Influenza Humana/virologia , Itália/epidemiologia , Masculino , Pessoa de Meia-Idade , Prebióticos/efeitos adversos , Prebióticos/economia , Gravidez , Probióticos/efeitos adversos , Probióticos/economia , Sistema de Registros , Fatores de Tempo , Resultado do TratamentoRESUMO
The objective of this study was to utilize extrusion cooking and hydrothermal treatment to produce resistant starch (RS) as an economical alternative to a batch-cooking process. A hydrothermal treatment (110 degrees C, 3 d) of batch-cooked and extruded starch samples facilitated propagation of heat-stable starch crystallites and increased the RS contents from 2.1% to 7.7% up to 17.4% determined using AOAC Method 991.43 for total dietary fiber. When starch samples were batch cooked and hydrothermally treated at a moisture content below 70%, acid-modified normal-maize starch (AMMS) produced a greater RS content than did native normal-maize starch (NMS). This was attributed to the partially hydrolyzed, smaller molecules in the AMMS, which had greater mobility and freedom than the larger molecules in the NMS. The RS contents of the batch-cooked and extruded AMMS products after the hydrothermal treatment were similar. A freezing treatment of the AMMS samples at -20 degrees C prior to the hydrothermal treatment did not increase the RS content. The DSC thermograms and the X-ray diffractograms showed that retrograded amylose and crystalline starch-lipid complex, which had melting temperatures above 100 degrees C, accounted for the RS contents.